Anaritide (Auriculin-Registered Trademark) is a 25-amino-acid synthetic form of atrial natriuretic peptide. Scios Nova was developing anaritide acetate for use in the treatment, prevention and diagnosis of acute renal failure, heart failure and hypertension. Scios suspended development of AURICULIN® anaritide based upon the results of an interim analysis of data from a 250-patient Phase III study in oliguric acute renal failure. The study was suspended due to the low probability that a positive outcome could be obtained with respect to its primary clinical endpoint, dialysis-free survival.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Bronchoprotective and bronchodilator activity of anaritide (human atrial natriuretic factor [102-126]) infusion in the anesthetized guinea pig. | 1988 |
|
| Effects of atrial natriuretic factor on coronary hemodynamics and myocardial energetics in patients with heart failure. | 1988 Jun |
|
| Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. | 1997 Mar 20 |
|
| Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. | 2009 |
Sample Use Guides
Acute tubular necrosis: The patients received a 24-hour intravenous infusion of either anaritide (0.2 microgram per kilogram of body weight per minute)
Route of Administration:
Intravenous
In in vitro perfused hydronephrotic rat kidney model Anaritide completely reversed the NE-induced AA vasoconstriction with an IC50 of 9.3 +/- 5.6 nM. In contrast, ANP caused a further decrease in EA diameter at concentrations up to 10(-8) M, and elicited a slight dilation of the EA at 10(-7) M.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C548
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2108934
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
C77221
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
16137704
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
C042703
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
m2133
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID401336852
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
1M00R25BPL
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
95896-08-5
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
6082
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
SUB05501MIG
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY | |||
|
Anaritide
Created by
admin on Sat Dec 16 00:14:46 GMT 2023 , Edited by admin on Sat Dec 16 00:14:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
